Clinical Trials Logo

Lymphoma, Mantle-cell clinical trials

View clinical trials related to Lymphoma, Mantle-cell.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05645744 Enrolling by invitation - Clinical trials for Diffuse Large B Cell Lymphoma

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Start date: September 29, 2021
Phase:
Study type: Observational

A long-term follow-up study to assess safety and efficacy in patients previously treated with Mustang Bio chimeric antigen receptor (CAR)-T cell investigational products.

NCT ID: NCT04911478 Enrolling by invitation - Clinical trials for Lymphoma, Non-Hodgkin

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

Start date: February 14, 2022
Phase:
Study type: Observational

The purpose of this study is to assess long-term side effects from subjects who receive an Adicet Bio γδ CAR T cell product. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years from the first administration of Adicet Bio allogeneic γδ CAR T cell product, subjects will be assessed for long-term safety and survival through collection of data that include safety, efficacy, pharmacokinetics and immunogenicity.

NCT ID: NCT04488354 Enrolling by invitation - Clinical trials for Waldenstrom Macroglobulinemia

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

Start date: January 21, 2021
Phase: Phase 1
Study type: Interventional

This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells

NCT ID: NCT01804686 Enrolling by invitation - Clinical trials for Chronic Lymphocytic Leukemia

A Long-term Extension Study of PCI-32765 (Ibrutinib)

CAN3001
Start date: September 9, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.